Vera’s Atacicept Sets A New Efficacy Bar With Phase III Results In IgAN
First-In-Class Drug Exceeds Expectations
Vera is the first company to report Phase III data for a dual inhibitor of APRIL and BAFF in IgA nephropathy. Atacicept provided a 42% placebo-adjusted reduction in proteinuria.
